$SLS

AI Analysis

Generated on May 13, 2026

AI Score
28/ 100
Sell$SLS

SELLAS Life Sciences Group

$SLSNASDAQHealthcareSmall-Cap

SELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies, with lead asset galinpepimut-S (GPS) for hematologic cancers.

Market Cap
$0.08B
Revenue (TTM)
$0.01B
N/A
Net Income (TTM)
-$0.03B
N/A
EPS (TTM)
-$1.20
P/E Ratio
N/A
Dividend Yield
0.0%
52-Week Range
$1-$5
Beta
1.95
Dimension Scores
Fundamental
15
Technical
32
Sentiment
38
Risk / Reward
22
Momentum
35
FundTechSentRiskMome
Financial Health
Profitability
20weak
Growth
38weak
Liquidity
30strong
Solvency
17moderate
Efficiency
13moderate

Valuation, technical analysis, investment thesis, risk assessment and more for $SLS

Free · No credit card required

Disclaimer: AI-generated analysis for educational purposes only. Not financial advice. Always consult a qualified financial advisor.

Explore more

Analyze any stock with AI

Get a structured equity research report covering fundamentals, technicals, sentiment, risk, and investment thesis — in about 60 seconds.